Financial Report: Abbott 3Q

Abbott 3Q

3Q Revenues: $8.7 billion (+12%)

3Q Earnings: $891.0 million (-40%)

YTD Revenues: $25.2 billion (+15%)

YTD Earnings: $3.2 billion (-24%)

Comments: Growth in the quarter was driven by worldwide pharmaceutical sales, up 22% to $4.9 billion. Humira sales were $1.7 billion in the quarter, up 13%. Trilipix/TriCor sales were $404 million (+22%). Niaspan sales were up 5% to $225 million. Kaletra sales were down 7% to $328 million and Lupron sales were down 3% to $189 million. Worldwide Diagnostics Sales were $916 million (+1%). Worldwide Vascular Sales were up 19% to $790 million. Worldwide Nutritional Sales were down 2% to $1.4 billion. Earnings in 2009 included a favorable patent litigation settlement and contractual payments from Takeda associated with the conclusion of the TAP joint venture.